Which has preferable earnings & valuation, DMRA or EWTX?

Edgewise Therapeutics is trading at a lower price-to-earnings ratio than Damora Therapeutics, Inc. Common Stock, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Damora Therapeutics, Inc. Common Stock N/A N/A -$209.84M -$3.37 N/A Edgewise Therapeutics N/A N/A -$167.79M -$1.85 N/A

Is DMRA or EWTX more profitable?

Edgewise Therapeutics' return on equity of -39.01% beat Damora Therapeutics, Inc. Common Stock's return on equity. Company Net Margins Return on Equity Return on Assets Damora Therapeutics, Inc. Common Stock N/A -176.39% -77.86% Edgewise Therapeutics N/A -39.01% -36.96%

Is DMRA or RLAY more profitable?

Relay Therapeutics' return on equity of -42.27% beat Damora Therapeutics, Inc. Common Stock's return on equity. Company Net Margins Return on Equity Return on Assets Damora Therapeutics, Inc. Common Stock N/A -176.39% -77.86% Relay Therapeutics N/A -42.27% -38.67%

Is DMRA or TNGX more profitable?

Tango Therapeutics' return on equity of -25.75% beat Damora Therapeutics, Inc. Common Stock's return on equity. Company Net Margins Return on Equity Return on Assets Damora Therapeutics, Inc. Common Stock N/A -176.39% -77.86% Tango Therapeutics N/A -25.75% -23.36%

Damora Therapeutics, Inc. Common Stock (DMRA) Competitors

$18.56 -1.69 (-8.35%)

As of 04:00 PM Eastern

Compare

DMRA vs. DNTH, EWTX, RLAY, ABCL, and TNGX

Should you buy Damora Therapeutics, Inc. Common Stock stock or one of its competitors? Damora Therapeutics, Inc. Common Stock's main competitors and comparable companies include Dianthus Therapeutics (DNTH), Edgewise Therapeutics (EWTX), Relay Therapeutics (RLAY), AbCellera Biologics (ABCL), and Tango Therapeutics (TNGX). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does Damora Therapeutics, Inc. Common Stock compare to Dianthus Therapeutics?

Dianthus Therapeutics (NASDAQ:DNTH) and Damora Therapeutics, Inc. Common Stock (NASDAQ:DMRA) are both healthcare companies, but which is the better business? We will contrast the two companies based on the strength of their institutional ownership, earnings, analyst recommendations, risk, profitability, dividends, media sentiment and valuation.

Dianthus Therapeutics has a beta of 1.35, meaning that its share price is 35% more volatile than the broader market. Comparatively, Damora Therapeutics, Inc. Common Stock has a beta of 1.43, meaning that its share price is 43% more volatile than the broader market.

Damora Therapeutics, Inc. Common Stock has a net margin of 0.00% compared to Dianthus Therapeutics' net margin of -10,096.95%. Dianthus Therapeutics' return on equity of -22.53% beat Damora Therapeutics, Inc. Common Stock's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Dianthus Therapeutics	-10,096.95%	-22.53%	-21.55%
Damora Therapeutics, Inc. Common Stock	N/A	-176.39%	-77.86%

In the previous week, Dianthus Therapeutics had 1 more articles in the media than Damora Therapeutics, Inc. Common Stock. MarketBeat recorded 4 mentions for Dianthus Therapeutics and 3 mentions for Damora Therapeutics, Inc. Common Stock. Dianthus Therapeutics' average media sentiment score of 1.06 beat Damora Therapeutics, Inc. Common Stock's score of 0.60 indicating that Dianthus Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Dianthus Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Damora Therapeutics, Inc. Common Stock	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Dianthus Therapeutics presently has a consensus price target of $129.83, indicating a potential upside of 59.17%. Damora Therapeutics, Inc. Common Stock has a consensus price target of $46.50, indicating a potential upside of 129.63%. Given Damora Therapeutics, Inc. Common Stock's stronger consensus rating and higher possible upside, analysts plainly believe Damora Therapeutics, Inc. Common Stock is more favorable than Dianthus Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Dianthus Therapeutics	1 Sell rating(s)	0 Hold rating(s)	13 Buy rating(s)	1 Strong Buy rating(s)	2.93
Damora Therapeutics, Inc. Common Stock	1 Sell rating(s)	1 Hold rating(s)	7 Buy rating(s)	3 Strong Buy rating(s)	3.00

47.5% of Dianthus Therapeutics shares are owned by institutional investors. Comparatively, 14.2% of Damora Therapeutics, Inc. Common Stock shares are owned by institutional investors. 3.0% of Dianthus Therapeutics shares are owned by company insiders. Comparatively, 0.4% of Damora Therapeutics, Inc. Common Stock shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Dianthus Therapeutics has higher revenue and earnings than Damora Therapeutics, Inc. Common Stock. Dianthus Therapeutics is trading at a lower price-to-earnings ratio than Damora Therapeutics, Inc. Common Stock, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Dianthus Therapeutics	$2.04M	2,191.19	-$162.34M	-$4.15	N/A
Damora Therapeutics, Inc. Common Stock	N/A	N/A	-$209.84M	-$3.37	N/A

Summary

Dianthus Therapeutics beats Damora Therapeutics, Inc. Common Stock on 9 of the 16 factors compared between the two stocks.

How does Damora Therapeutics, Inc. Common Stock compare to Edgewise Therapeutics?

Damora Therapeutics, Inc. Common Stock (NASDAQ:DMRA) and Edgewise Therapeutics (NASDAQ:EWTX) are both healthcare companies, but which is the better stock? We will compare the two businesses based on the strength of their earnings, dividends, analyst recommendations, valuation, profitability, risk, institutional ownership and media sentiment.

Edgewise Therapeutics is trading at a lower price-to-earnings ratio than Damora Therapeutics, Inc. Common Stock, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Damora Therapeutics, Inc. Common Stock	N/A	N/A	-$209.84M	-$3.37	N/A
Edgewise Therapeutics	N/A	N/A	-$167.79M	-$1.85	N/A

Edgewise Therapeutics' return on equity of -39.01% beat Damora Therapeutics, Inc. Common Stock's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Damora Therapeutics, Inc. Common Stock	N/A	-176.39%	-77.86%
Edgewise Therapeutics	N/A	-39.01%	-36.96%

In the previous week, Edgewise Therapeutics had 1 more articles in the media than Damora Therapeutics, Inc. Common Stock. MarketBeat recorded 4 mentions for Edgewise Therapeutics and 3 mentions for Damora Therapeutics, Inc. Common Stock. Damora Therapeutics, Inc. Common Stock's average media sentiment score of 0.60 beat Edgewise Therapeutics' score of 0.20 indicating that Damora Therapeutics, Inc. Common Stock is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Damora Therapeutics, Inc. Common Stock	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Edgewise Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Neutral

Damora Therapeutics, Inc. Common Stock has a beta of 1.43, suggesting that its share price is 43% more volatile than the broader market. Comparatively, Edgewise Therapeutics has a beta of 0.35, suggesting that its share price is 65% less volatile than the broader market.

Damora Therapeutics, Inc. Common Stock presently has a consensus target price of $46.50, suggesting a potential upside of 129.63%. Edgewise Therapeutics has a consensus target price of $51.33, suggesting a potential upside of 33.51%. Given Damora Therapeutics, Inc. Common Stock's stronger consensus rating and higher probable upside, equities analysts plainly believe Damora Therapeutics, Inc. Common Stock is more favorable than Edgewise Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Damora Therapeutics, Inc. Common Stock	1 Sell rating(s)	1 Hold rating(s)	7 Buy rating(s)	3 Strong Buy rating(s)	3.00
Edgewise Therapeutics	1 Sell rating(s)	1 Hold rating(s)	8 Buy rating(s)	1 Strong Buy rating(s)	2.82

14.2% of Damora Therapeutics, Inc. Common Stock shares are owned by institutional investors. 0.4% of Damora Therapeutics, Inc. Common Stock shares are owned by company insiders. Comparatively, 21.3% of Edgewise Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Summary

Damora Therapeutics, Inc. Common Stock and Edgewise Therapeutics tied by winning 7 of the 14 factors compared between the two stocks.

How does Damora Therapeutics, Inc. Common Stock compare to Relay Therapeutics?

Damora Therapeutics, Inc. Common Stock (NASDAQ:DMRA) and Relay Therapeutics (NASDAQ:RLAY) are both healthcare companies, but which is the superior investment? We will contrast the two businesses based on the strength of their analyst recommendations, dividends, profitability, earnings, institutional ownership, media sentiment, valuation and risk.

Damora Therapeutics, Inc. Common Stock has a beta of 1.43, suggesting that its share price is 43% more volatile than the broader market. Comparatively, Relay Therapeutics has a beta of 1.72, suggesting that its share price is 72% more volatile than the broader market.

In the previous week, Relay Therapeutics had 8 more articles in the media than Damora Therapeutics, Inc. Common Stock. MarketBeat recorded 11 mentions for Relay Therapeutics and 3 mentions for Damora Therapeutics, Inc. Common Stock. Relay Therapeutics' average media sentiment score of 0.66 beat Damora Therapeutics, Inc. Common Stock's score of 0.60 indicating that Relay Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Damora Therapeutics, Inc. Common Stock	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Relay Therapeutics	4 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Relay Therapeutics' return on equity of -42.27% beat Damora Therapeutics, Inc. Common Stock's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Damora Therapeutics, Inc. Common Stock	N/A	-176.39%	-77.86%
Relay Therapeutics	N/A	-42.27%	-38.67%

Damora Therapeutics, Inc. Common Stock presently has a consensus target price of $46.50, indicating a potential upside of 129.63%. Relay Therapeutics has a consensus target price of $25.92, indicating a potential upside of 44.14%. Given Damora Therapeutics, Inc. Common Stock's stronger consensus rating and higher probable upside, equities research analysts plainly believe Damora Therapeutics, Inc. Common Stock is more favorable than Relay Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Damora Therapeutics, Inc. Common Stock	1 Sell rating(s)	1 Hold rating(s)	7 Buy rating(s)	3 Strong Buy rating(s)	3.00
Relay Therapeutics	1 Sell rating(s)	1 Hold rating(s)	10 Buy rating(s)	2 Strong Buy rating(s)	2.93

14.2% of Damora Therapeutics, Inc. Common Stock shares are held by institutional investors. Comparatively, 97.0% of Relay Therapeutics shares are held by institutional investors. 0.4% of Damora Therapeutics, Inc. Common Stock shares are held by insiders. Comparatively, 5.0% of Relay Therapeutics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Damora Therapeutics, Inc. Common Stock has higher earnings, but lower revenue than Relay Therapeutics. Relay Therapeutics is trading at a lower price-to-earnings ratio than Damora Therapeutics, Inc. Common Stock, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Damora Therapeutics, Inc. Common Stock	N/A	N/A	-$209.84M	-$3.37	N/A
Relay Therapeutics	$15.35M	256.69	-$276.48M	-$1.57	N/A

Summary

Relay Therapeutics beats Damora Therapeutics, Inc. Common Stock on 10 of the 15 factors compared between the two stocks.

How does Damora Therapeutics, Inc. Common Stock compare to AbCellera Biologics?

AbCellera Biologics (NASDAQ:ABCL) and Damora Therapeutics, Inc. Common Stock (NASDAQ:DMRA) are both healthcare companies, but which is the superior investment? We will contrast the two businesses based on the strength of their analyst recommendations, valuation, institutional ownership, dividends, media sentiment, profitability, earnings and risk.

In the previous week, AbCellera Biologics had 6 more articles in the media than Damora Therapeutics, Inc. Common Stock. MarketBeat recorded 9 mentions for AbCellera Biologics and 3 mentions for Damora Therapeutics, Inc. Common Stock. Damora Therapeutics, Inc. Common Stock's average media sentiment score of 0.60 beat AbCellera Biologics' score of 0.43 indicating that Damora Therapeutics, Inc. Common Stock is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
AbCellera Biologics	0 Very Positive mention(s)	1 Positive mention(s)	6 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Damora Therapeutics, Inc. Common Stock	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Damora Therapeutics, Inc. Common Stock has a net margin of 0.00% compared to AbCellera Biologics' net margin of -248.83%. AbCellera Biologics' return on equity of -17.49% beat Damora Therapeutics, Inc. Common Stock's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
AbCellera Biologics	-248.83%	-17.49%	-12.36%
Damora Therapeutics, Inc. Common Stock	N/A	-176.39%	-77.86%

AbCellera Biologics has higher revenue and earnings than Damora Therapeutics, Inc. Common Stock. AbCellera Biologics is trading at a lower price-to-earnings ratio than Damora Therapeutics, Inc. Common Stock, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
AbCellera Biologics	$75.13M	51.58	-$146.41M	-$0.54	N/A
Damora Therapeutics, Inc. Common Stock	N/A	N/A	-$209.84M	-$3.37	N/A

AbCellera Biologics presently has a consensus price target of $13.89, indicating a potential upside of 9.88%. Damora Therapeutics, Inc. Common Stock has a consensus price target of $46.50, indicating a potential upside of 129.63%. Given Damora Therapeutics, Inc. Common Stock's stronger consensus rating and higher probable upside, analysts clearly believe Damora Therapeutics, Inc. Common Stock is more favorable than AbCellera Biologics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
AbCellera Biologics	1 Sell rating(s)	2 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	2.70
Damora Therapeutics, Inc. Common Stock	1 Sell rating(s)	1 Hold rating(s)	7 Buy rating(s)	3 Strong Buy rating(s)	3.00

AbCellera Biologics has a beta of 1.41, indicating that its share price is 41% more volatile than the broader market. Comparatively, Damora Therapeutics, Inc. Common Stock has a beta of 1.43, indicating that its share price is 43% more volatile than the broader market.

61.4% of AbCellera Biologics shares are held by institutional investors. Comparatively, 14.2% of Damora Therapeutics, Inc. Common Stock shares are held by institutional investors. 28.4% of AbCellera Biologics shares are held by company insiders. Comparatively, 0.4% of Damora Therapeutics, Inc. Common Stock shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Summary

AbCellera Biologics and Damora Therapeutics, Inc. Common Stock tied by winning 8 of the 16 factors compared between the two stocks.

How does Damora Therapeutics, Inc. Common Stock compare to Tango Therapeutics?

Damora Therapeutics, Inc. Common Stock (NASDAQ:DMRA) and Tango Therapeutics (NASDAQ:TNGX) are both healthcare companies, but which is the superior investment? We will compare the two businesses based on the strength of their risk, institutional ownership, media sentiment, analyst recommendations, earnings, profitability, dividends and valuation.

Tango Therapeutics has higher revenue and earnings than Damora Therapeutics, Inc. Common Stock. Tango Therapeutics is trading at a lower price-to-earnings ratio than Damora Therapeutics, Inc. Common Stock, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Damora Therapeutics, Inc. Common Stock	N/A	N/A	-$209.84M	-$3.37	N/A
Tango Therapeutics	$53.81M	75.73	-$101.59M	-$0.85	N/A

Damora Therapeutics, Inc. Common Stock has a beta of 1.43, indicating that its share price is 43% more volatile than the broader market. Comparatively, Tango Therapeutics has a beta of 1.17, indicating that its share price is 17% more volatile than the broader market.

In the previous week, Tango Therapeutics had 2 more articles in the media than Damora Therapeutics, Inc. Common Stock. MarketBeat recorded 5 mentions for Tango Therapeutics and 3 mentions for Damora Therapeutics, Inc. Common Stock. Tango Therapeutics' average media sentiment score of 0.89 beat Damora Therapeutics, Inc. Common Stock's score of 0.60 indicating that Tango Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Damora Therapeutics, Inc. Common Stock	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Tango Therapeutics	2 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Tango Therapeutics' return on equity of -25.75% beat Damora Therapeutics, Inc. Common Stock's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Damora Therapeutics, Inc. Common Stock	N/A	-176.39%	-77.86%
Tango Therapeutics	N/A	-25.75%	-23.36%

Damora Therapeutics, Inc. Common Stock currently has a consensus target price of $46.50, suggesting a potential upside of 129.63%. Tango Therapeutics has a consensus target price of $43.46, suggesting a potential upside of 79.82%. Given Damora Therapeutics, Inc. Common Stock's stronger consensus rating and higher possible upside, equities analysts clearly believe Damora Therapeutics, Inc. Common Stock is more favorable than Tango Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Damora Therapeutics, Inc. Common Stock	1 Sell rating(s)	1 Hold rating(s)	7 Buy rating(s)	3 Strong Buy rating(s)	3.00
Tango Therapeutics	1 Sell rating(s)	2 Hold rating(s)	13 Buy rating(s)	0 Strong Buy rating(s)	2.75

14.2% of Damora Therapeutics, Inc. Common Stock shares are owned by institutional investors. Comparatively, 79.0% of Tango Therapeutics shares are owned by institutional investors. 0.4% of Damora Therapeutics, Inc. Common Stock shares are owned by company insiders. Comparatively, 6.5% of Tango Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Summary

Tango Therapeutics beats Damora Therapeutics, Inc. Common Stock on 10 of the 15 factors compared between the two stocks.

Get Damora Therapeutics, Inc. Common Stock News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding DMRA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

DMRA vs. The Competition

Export

Metric	Damora Therapeutics, Inc. Common Stock	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$1.25B	$3.93B	$7.27B	$13.21B
Dividend Yield	N/A	3.65%	2.52%	22.89%
P/E Ratio	-5.51	9.71	193.11	18.97
Price / Sales	N/A	1,149.10	561.77	81.05
Price / Cash	N/A	118.50	77.16	53.04
Price / Book	-0.17	16.95	10.71	6.03
Net Income	-$209.84M	-$22.69M	$3.50B	$380.34M
7 Day Performance	-5.06%	-4.83%	-3.18%	-3.04%
1 Month Performance	-33.95%	-12.20%	-6.61%	-5.16%
1 Year Performance	45.57%	8.87%	3.69%	-2.48%

Damora Therapeutics, Inc. Common Stock Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
DMRA Damora Therapeutics, Inc. Common Stock	3.2024 of 5 stars	$18.56 -8.3%	$46.50 +150.5%	+60.0%	$1.25B	N/A	N/A	40	Analyst Upgrade
DNTH Dianthus Therapeutics	2.6332 of 5 stars	$85.40 -3.0%	$129.83 +52.0%	+136.7%	$4.82B	$2.04M	N/A	92	News Coverage
EWTX Edgewise Therapeutics	2.7126 of 5 stars	$40.02 -0.7%	$51.33 +28.3%	+154.5%	$4.38B	N/A	N/A	127
RLAY Relay Therapeutics	2.4332 of 5 stars	$18.74 -3.4%	$25.92 +38.3%	+176.6%	$4.25B	$15.35M	N/A	192
ABCL AbCellera Biologics	1.857 of 5 stars	$13.15 -4.6%	$13.38 +1.7%	+128.6%	$4.23B	$75.13M	N/A	562	News Coverage Analyst Forecast

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:DMRA) was last updated on 10/13/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Damora Therapeutics, Inc. Common Stock (DMRA) Competitors

DMRA vs. DNTH, EWTX, RLAY, ABCL, and TNGX

How does Damora Therapeutics, Inc. Common Stock compare to Dianthus Therapeutics?

Summary

How does Damora Therapeutics, Inc. Common Stock compare to Edgewise Therapeutics?

Summary

How does Damora Therapeutics, Inc. Common Stock compare to Relay Therapeutics?

Summary

How does Damora Therapeutics, Inc. Common Stock compare to AbCellera Biologics?

Summary

How does Damora Therapeutics, Inc. Common Stock compare to Tango Therapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

DMRA vs. The Competition

Damora Therapeutics, Inc. Common Stock Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Damora Therapeutics, Inc. Common Stock (DMRA) Competitors

DMRA vs. DNTH, EWTX, RLAY, ABCL, and TNGX

How does Damora Therapeutics, Inc. Common Stock compare to Dianthus Therapeutics?

Which has more volatility & risk, DNTH or DMRA?

Is DNTH or DMRA more profitable?

Does the media refer more to DNTH or DMRA?

Do analysts recommend DNTH or DMRA?

Do insiders and institutionals have more ownership in DNTH or DMRA?

Which has stronger valuation and earnings, DNTH or DMRA?

Summary

How does Damora Therapeutics, Inc. Common Stock compare to Edgewise Therapeutics?

Which has preferable earnings & valuation, DMRA or EWTX?

Is DMRA or EWTX more profitable?

Does the media favor DMRA or EWTX?

Which has more risk and volatility, DMRA or EWTX?

Do analysts recommend DMRA or EWTX?

Do institutionals & insiders hold more shares of DMRA or EWTX?

Summary

How does Damora Therapeutics, Inc. Common Stock compare to Relay Therapeutics?

Which has more volatility and risk, DMRA or RLAY?

Does the media favor DMRA or RLAY?

Is DMRA or RLAY more profitable?

Do analysts recommend DMRA or RLAY?

Do insiders & institutionals believe in DMRA or RLAY?

Which has preferable valuation and earnings, DMRA or RLAY?

Summary

How does Damora Therapeutics, Inc. Common Stock compare to AbCellera Biologics?

Does the media refer more to ABCL or DMRA?

Is ABCL or DMRA more profitable?

Which has better valuation and earnings, ABCL or DMRA?

Do analysts rate ABCL or DMRA?

Which has more risk and volatility, ABCL or DMRA?

Do institutionals and insiders have more ownership in ABCL or DMRA?

Summary

How does Damora Therapeutics, Inc. Common Stock compare to Tango Therapeutics?

Which has preferable earnings and valuation, DMRA or TNGX?

Which has more volatility & risk, DMRA or TNGX?

Does the media prefer DMRA or TNGX?

Is DMRA or TNGX more profitable?

Do analysts recommend DMRA or TNGX?

Do institutionals & insiders have more ownership in DMRA or TNGX?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

DMRA vs. The Competition

Damora Therapeutics, Inc. Common Stock Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools